drugset / Trial / NCT05502315
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Phase 2
Active not recruiting
47 enrolled
Rana McKay, MD
Bristol-Myers Squibb · collabExelixis · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2023-02-02
- Primary completion
- 2026-07-12
- Completion
- 2027-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |